Study of efficacy of topical rituximab encapsulated in nanoparticle in oral pemphigus vulgaris- a randomised double blinded placebo controlled trial

Dr SUJAY KHANDPUR0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Patients with predominant oral Pemphigus vulgaris (defined as oral involvement with cutaneous involvement less than 1%) or
•pure oral mucosal involvement diagnosed on basis of clinical features and ELISA for desmoglein 3 antibody with or without positive tzanck smear and mucosal biopsy
•2. Patients in age group of 18-72 years.
•3. Patients giving consent for participating in study and obtaining mucosal biopsies.

•1. Patients with pemphigus vulgaris with cutaneous involvement more than 1%.
•2. Patients unwilling to give consent for study.
•3. Patients with history of significant reaction to intravenous rituximab
•4. Patients with severe comorbid illness like patients with malignancy, cardiac failure and uncontrolled diabetes mellitus.

发起方

Dr SUJAY KHANDPUR